tradingkey.logo
tradingkey.logo
Search

Beigene Ltd

ONC
Add to Watchlist
289.990USD
+10.100+3.61%
Close 06/29, 16:00ETQuotes delayed by 15 min
29.51BMarket Cap
62.12P/E TTM

TradingKey Stock Score of Beigene Ltd

Currency: USD Updated: 2026-06-26

Key Insights

Beigene Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 406.57.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beigene Ltd's Score

Industry at a Glance

Industry Ranking
58 / 387
Overall Ranking
152 / 4566
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Beigene Ltd Highlights

StrengthsRisks
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 5.34B.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 117.30% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 59.96, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 40.42M shares, increasing 4.63% quarter-over-quarter.
Held by Matthews International Capital Management
Star Investor Matthews International Capital Management holds 12.60K shares of this stock.

Analyst Rating

Based on 27 analysts
Buy
Current Rating
406.573
Target Price
+45.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Beigene Ltd?

The TradingKey Stock Score provides a comprehensive assessment of Beigene Ltd based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Beigene Ltd’s performance and outlook.

How do we generate the financial health score of Beigene Ltd?

To generate the financial health score of Beigene Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Beigene Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Beigene Ltd.

How do we generate the company valuation score of Beigene Ltd?

To generate the company valuation score of Beigene Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Beigene Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Beigene Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Beigene Ltd.

How do we generate the earnings forecast score of Beigene Ltd?

To calculate the earnings forecast score of Beigene Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Beigene Ltd’s future.

How do we generate the price momentum score of Beigene Ltd?

When generating the price momentum score for Beigene Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Beigene Ltd’s prices. A higher score indicates a more stable short-term price trend for Beigene Ltd.

How do we generate the institutional confidence score of Beigene Ltd?

To generate the institutional confidence score of Beigene Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Beigene Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Beigene Ltd.

How do we generate the risk management score of Beigene Ltd?

To assess the risk management score of Beigene Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Beigene Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Beigene Ltd.
KeyAI